We came across a bullish thesis on Novo Nordisk A/S (NYSE:NVO) on ValueInvestorsClub by cable888. In this article, we will ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Outsourcing Facilities Association and North American Custom Laboratories allege the FDA removed semaglutide from its ...

New diabetes medications are pressuring Medicare Part D financially as they drive up prescription drug costs amid rising ...

Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...

The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...

A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...

In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing ...

Since, Viking's clinical data remain strong, and the company aims to launch a phase 3 trial for the injectable version of ...